EP4520322A1 — Pharmaceutical compositions containing enzalutamide
Assigned to Alfred E Tiefenbacher GmbH and Co KG · Expires 2025-03-12 · 1y expired
What this patent protects
The present invention relates to a pharmaceutical composition comprising or consisting of an amorphous solid dispersion of enzalutamide as active agent in a mixture of hydroxypropyl methylcellulose phthalate and cellulose acetate phthalate as pharmaceutically acceptable excipient…
USPTO Abstract
The present invention relates to a pharmaceutical composition comprising or consisting of an amorphous solid dispersion of enzalutamide as active agent in a mixture of hydroxypropyl methylcellulose phthalate and cellulose acetate phthalate as pharmaceutically acceptable excipients, its production process as well as its use in the treatment of a hyperproliferative disorder.
Drugs covered by this patent
- Xtandi (enzalutamide) · Astellas Pharma
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.